Is There a Role for Immunotherapy in Prostate Cancer?

In the last decade, immunotherapy has revolutionized the treatment landscape of several hematological and solid malignancies, reporting unprecedented response rates. Unfortunately, this is not the case for metastatic castration-resistant prostate cancer (mCRPC), as several phase I and II trials asse...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cells (Basel, Switzerland) Jg. 9; H. 9; S. 2051
Hauptverfasser:	Rizzo, Alessandro, Mollica, Veronica, Cimadamore, Alessia, Santoni, Matteo, Scarpelli, Marina, Giunchi, Francesca, Cheng, Liang, Lopez-Beltran, Antonio, Fiorentino, Michelangelo, Montironi, Rodolfo, Massari, Francesco
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland MDPI AG 08.09.2020 MDPI
Schlagworte:	Antibodies Antitumor agents Biomarkers Cancer vaccines Care and treatment Castration Clinical trials CTLA-4 CTLA-4 protein Cytotoxicity FDA approval Humans Immune checkpoint Immunotherapy Immunotherapy - methods Kidney cancer Lymphocytes T Male Malignancy Melanoma Metastases Metastasis Methods Monoclonal antibodies Mutation pd-1 PD-1 protein predictive biomarkers Prostate cancer Prostatic Neoplasms - immunology Prostatic Neoplasms - therapy Radiation therapy Review Skin cancer Tumors Vaccines Italy predictive biomarkers prostate cancer vaccines immunotherapy combination therapy CTLA-4 immune checkpoint inhibitors pd-1
ISSN:	2073-4409, 2073-4409
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!